You might be resistant to CRISPR-Cas9 – but there are still ways around it
It looks like there could be a setback for CRISPR-Cas9 as a gene therapy option for humans. Last year ended well for the gene-editing tool, and we got one step…
It looks like there could be a setback for CRISPR-Cas9 as a gene therapy option for humans. Last year ended well for the gene-editing tool, and we got one step…
How much? I imagine that question came up eventually at one of the meetings of whichever team decides pricing strategies at Novartis. And they came up with an answer: 475000 $. Four…